Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/01/2010WO2010036928A1 Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
04/01/2010WO2010036917A1 Prevention and treatment of cancer with ras gene mutation
04/01/2010WO2010036910A1 Heart protection by administering an amp-activated protein kinase activator
04/01/2010WO2010036908A1 Use of benzoxazole compounds in the treatment of malaria
04/01/2010WO2010036905A1 Benzoxazole compounds and methods of use
04/01/2010WO2010036904A2 Preparation of valganciclovir and its salts
04/01/2010WO2010036896A1 Hepatitis c virus inhibitors
04/01/2010WO2010036878A1 Use of trpv1 receptor agonists in cervical pain and labor
04/01/2010WO2010036873A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
04/01/2010WO2010036871A1 Macrocyclic compounds as hepatitis c virus inhibitors
04/01/2010WO2010036822A1 Patient populations and treatment methods
04/01/2010WO2010036821A1 Methods and compositions for treating respiratory disorders
04/01/2010WO2010036814A1 Selective seprase inhibitors
04/01/2010WO2010036799A1 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis "
04/01/2010WO2010036796A1 Pyridineamine derivatives
04/01/2010WO2010036773A1 Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives
04/01/2010WO2010036702A1 Liquid formulations of bendamustine
04/01/2010WO2010036698A1 Substituted alpha-l-bicyclic nucleosides
04/01/2010WO2010036696A1 Cyclohexenyl nucleic acid analogs
04/01/2010WO2010036686A1 Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation
04/01/2010WO2010036640A2 Compounds for the treatment of inflammatory disorders
04/01/2010WO2010036638A2 Compounds for the treatment of inflammatory disorders
04/01/2010WO2010036632A1 Azaindazole compounds as ccr1 receptor antagonists
04/01/2010WO2010036631A2 Compounds which selectively modulate the cb2 receptor
04/01/2010WO2010036630A2 Compounds which selectively modulate the cb2 receptor
04/01/2010WO2010036629A2 Fused multicyclic compounds as protein kinase inhibitors
04/01/2010WO2010036613A1 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
04/01/2010WO2010036600A1 Pharmaceutical compositions of atorvastatin
04/01/2010WO2010036567A2 Harmine compounds for promoting bone growth
04/01/2010WO2010036551A1 Hepatitis c virus inhibitors
04/01/2010WO2010036544A1 Oxazolobenzimidazole derivatives
04/01/2010WO2010036497A2 Selective estrogen receptor modulator
04/01/2010WO2010036427A1 Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
04/01/2010WO2010036407A2 Antiviral nucleoside analogs
04/01/2010WO2010036404A2 Novel retinamide retinoic acid metabolism blocking agents
04/01/2010WO2010036401A1 Methods and compositions using selective delta opioid receptor-1 agonists, delta opioid receptor-2 antagonists, and/or mu opioid receptor antagonists for treatment of substance-related disorders
04/01/2010WO2010036399A2 Antiviral drugs for treatment of arenavirus infection
04/01/2010WO2010036380A1 Heterocyclic kinase inhibitors
04/01/2010WO2010036362A1 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
04/01/2010WO2010036357A1 Derivatives of 1-amino-2-cyclobutylethylboronic acid
04/01/2010WO2010036329A2 Process for making quinolone compounds
04/01/2010WO2010036316A1 Urea and carbamate compounds and analogs as kinase inhibitors
04/01/2010WO2010036283A1 Disposable fluid applicator
04/01/2010WO2010036213A1 3-deazaneplanocin derivatives
04/01/2010WO2010036111A1 Means and methods for counteracting, preventing and/or determining fibrosis or a risk of fibrosis
04/01/2010WO2010036052A2 Composition containing 4-o-methylhonokiol for treating or preventing amyloid- related diseases
04/01/2010WO2010036005A2 Pharmaceutical composition comprising risedronic acid or a salt thereof and vitamin d
04/01/2010WO2010035915A1 Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists
04/01/2010WO2010035833A1 Therapeutic agent for tympanites in ruminant animal
04/01/2010WO2010035806A1 Solid pharmaceutical composition
04/01/2010WO2010035768A1 Prophylactic or therapeutic agent for retinal diseases comprising polyalkylene glycol as active ingredient
04/01/2010WO2010035766A1 Method for producing triazole derivative
04/01/2010WO2010035751A1 Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
04/01/2010WO2010035745A1 Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
04/01/2010WO2010035727A1 Novel pyrrolinone derivative and medicinal composition containing same
04/01/2010WO2010035675A1 Immunopotentiator or antiallergic agent
04/01/2010WO2010035299A1 Use of triterpenic and anthraquinone glycosides as substances exerting hydragogue activity on mucosa of the upper respiratory tract, for the treatment of upper respiratory tract diseases
04/01/2010WO2010035282A1 Pharmaceutical compositions comprising deferasirox
04/01/2010WO2010035273A2 Novel gastroretentive delivery system
04/01/2010WO2010035268A2 Device for photodynamical therapy of cancer
04/01/2010WO2010035253A1 Effective nitric oxide generating preparations
04/01/2010WO2010035228A1 Method for producing phenolphthalein using a heteropolyacid catalyst
04/01/2010WO2010035221A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
04/01/2010WO2010035220A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
04/01/2010WO2010035219A2 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
04/01/2010WO2010035217A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
04/01/2010WO2010035166A1 Benzamide derivatives
04/01/2010WO2010035119A2 Vaccine adjuvants
04/01/2010WO2010035111A1 A process for the preparation of rotigotine
04/01/2010WO2010035094A1 Polymorphic form of calcium acamprosate
04/01/2010WO2010035076A1 Individual 5-fluorouracile dose optimization in folfiri treatment
04/01/2010WO2010035052A1 Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
04/01/2010WO2010035047A1 Binary compositions comprising an no-donor and an a-smase inhibitor for the treatment of respiratory diseases
04/01/2010WO2010035032A1 Calcium ion channel modulators & uses thereof
04/01/2010WO2010035026A1 Use of nmda activity enhancers to treat hypersomnia, reduced wakefulness or reduced vigilance
04/01/2010WO2010034996A1 Crystalline acid addition salts and their use as enzyme inhibitors
04/01/2010WO2010034917A2 Monoester of n-undecylenoyl phenylalanine and polyol, method for preparing same, and use of said esters as a skin lightening agent
04/01/2010WO2010034863A1 Use of kinase inhibitors for the preparation of pharmaceutical compositions for treatment of parkinson’s disease, pharmaceutical compositions and diagnostic procedure for parkinson’s disease
04/01/2010WO2010034853A1 Utilization of xylitol or its derivatives for taste-masking chemotherapy drugs of the quinolone-o-naphthyridone carboxylic acid group administrated in food intended for pigs
04/01/2010WO2010034838A2 New chemical compounds
04/01/2010WO2010034806A1 Anhydrate and hydrate forms of strontium ranelate
04/01/2010WO2010034799A1 3h-imidaz0 [4, 5-b] pyridine- 6 -carboxamides as anti -inflammatory agents
04/01/2010WO2010034798A1 3h-imidazo [4, 5-c] pyridine-6-carboxamides as anti -inflammatory agents
04/01/2010WO2010034797A1 1h-benzimidazole-5-carboxamides as anti-inflammatory agents
04/01/2010WO2010034796A1 1h-benz imidazole-5-carboxamides as anti-inflammatory agents
04/01/2010WO2010034790A1 Protease inhibitors
04/01/2010WO2010034789A1 Protease inhibitors
04/01/2010WO2010034788A1 Protease inhibitors
04/01/2010WO2010034779A2 Composition and method for treatment of preterm labor
04/01/2010WO2010034774A1 Compound for local deletion of tumors
04/01/2010WO2010034758A2 dsRNA FOR TREATING VIRAL INFECTION
04/01/2010WO2010034740A1 (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
04/01/2010WO2010034720A1 Methods for prolonging the health benefits triggered by a dietary restriction using a sphingosine kinase inhibitor
04/01/2010WO2010034707A1 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
04/01/2010WO2010034706A1 Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
04/01/2010WO2010034700A1 Treating cancer by modulating rna helicases
04/01/2010WO2010034693A1 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
04/01/2010WO2010034671A1 Pyrine or pyrazine derivatives for treating hcv
04/01/2010WO2010034670A2 Host cell kinases as targets for antiviral therapies against hcv infection
04/01/2010WO2010034657A1 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
1 ... 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 ... 7860